Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
李斯特菌载体多抗原结核疫苗的优化和高级概念验证研究
基本信息
- 批准号:10308053
- 负责人:
- 金额:$ 120.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-12-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdjuvantAerosolsAffectAmino Acid SubstitutionAnimalsAntigensAttenuatedBCG LiveBCG VaccineBioterrorismCaviaClinical ResearchCollaborationsDNA cassetteDevelopmentDiseaseDoseELF3 geneEvaluationFrancisella tularensisGenerationsGlycoproteinsGoalsHumanImmune responseImmunityImmunizationImmunizeLaboratoriesLeadListeriaListeria monocytogenesModelingMusMycobacterium bovisMycobacterium tuberculosisMycobacterium tuberculosis antigensPatientsPersonsPlanet EarthPrimatesProteinsPublic HealthPulmonary TuberculosisRecombinantsResearchRiskRouteSafetySystemTestingTuberculosisTuberculosis VaccinesTularemiaVaccinatedVaccinesVirulenceVirulentVirusbooster vaccinecancer cellcostearly childhoodefficacy studyfight againstguinea pig modelimmunogenicityimprovedlead candidatemacrophagemouse modelnonhuman primatenovelpathogenpathogenic bacteriapreclinical developmentprotein expressionrecombinant viral vectorsecretory proteinvaccination strategyvaccine candidatevaccine immunogenicityvaccine safetyvectorvector vaccine
项目摘要
PROJECT SUMMARY
Tuberculosis (TB) is one of the world's most important diseases, and a safe and effective vaccine against the
causative agent Mycobacterium tuberculosis (Mtb) that is more potent than the currently available only partially
effective M. bovis strain Bacille Calmette-Guérin (BCG) vaccine is sorely needed. It is generally acknowledged
that both an improved replacement vaccine for BCG and a potent heterologous booster vaccine are needed in
the fight against TB. The purpose of this project is to optimize and conduct advanced proof-of-concept studies
in small animals and non-human primates (NHP) of a second-generation heterologous multiantigenic
recombinant attenuated Listeria monocytogenes-vectored vaccine against TB.
Live attenuated recombinant Listeria monocytogenes (rLm) vaccines offer major advantages over other
approaches to booster vaccines, including protein in adjuvant and virus-vectored vaccines, in terms of cost,
ease of manufacture, immunogenicity and efficacy. In preliminary studies, we have identified an improved
multi-deletional Listeria vector (Lm ΔactA ΔinlB prfA*) and demonstrated that rLm vaccines expressing four key
immunoprotective Mtb proteins (rLmMtb4Ag) substantially augment protective immunity when used as a
heterologous booster vaccine in a prime-boost vaccination strategy against Mtb aerosol challenge in mice and
guinea pigs. Moreover, delivering the immunoprotective Mtb protein via a first generation rLm vector was more
efficacious than delivering it via a recombinant viral vector or administering it with a potent adjuvant.
The goal of this application is to optimize expression of an Lm-vectored vaccine expressing 4 Mtb
antigens; expand its antigen repertoire to six antigens to increase its potency; and to evaluate the optimized
final lead rLm vaccine candidate for safety, immunogenicity and efficacy as a standalone vaccine and as a
heterologous booster vaccine to BCG-primed animals in mouse, guinea pig, and non-human primate (NHP)
models of pulmonary TB. We shall accomplish this goal by: a) Optimizing the protein expression cassette of
rLmMtb4Ag vaccine; systematically evaluating additional novel Mtb antigens for immunogenicity and efficacy in
mice, selecting the top two antigens, and subsequently constructing a rLmMtb6Ag lead vaccine candidate; b)
Conducting comprehensive proof-of-concept studies of the optimized rLmMtb6Ag lead vaccine candidate for
safety, immunogenicity, and efficacy as standalone and heterologous booster vaccine in the mouse model of
pulmonary TB; c) Conducting selected proof-of-concept studies of the lead rLmMtb6Ag vaccine as a standa-
lone and heterologous booster vaccine for safety, immunogenicity and efficacy in a guinea pig model of
pulmonary TB; and d) as Aeras requires proof-of-concept in NHP for a vaccine to enter preclinical develop-
ment, evaluating the lead rLmMtb6Ag candidate as a standalone vaccine for safety, immunogenicity and
efficacy in a NHP model of pulmonary TB in collaboration with Aeras, Bioqual, and Tulane National Primate
Research Centre.
项目总结
结核病是世界上最重要的疾病之一,是预防结核病的一种安全有效的疫苗。
结核分枝杆菌(Mtb),比目前仅有的部分有效
目前迫切需要有效的牛分枝杆菌卡介苗疫苗。这是公认的
需要一种改进的卡介苗替代疫苗和一种有效的异种加强疫苗
与结核病作斗争。该项目的目的是优化和进行高级概念验证研究
在小动物和非人灵长类动物(NHP)中的第二代异源多抗原
结核重组单核细胞增多性李斯特氏菌载体疫苗。
与其他疫苗相比,减毒重组单核细胞增生性李斯特菌(RLM)活疫苗具有重大优势
加强疫苗的方法,包括佐剂和病毒载体疫苗中的蛋白质,在成本方面,
易于制造、免疫原性和功效。在初步研究中,我们发现了一种改进的
多缺失李斯特氏菌载体(LMΔActaΔin1B PrFA*),并证明了表达四个关键基因的RLm疫苗
免疫保护性Mtb蛋白(RLmMtb4Ag)作为一种
异种强化疫苗在小鼠和小鼠中对抗结核分枝杆菌气溶胶攻击的加强免疫策略
豚鼠。此外,通过第一代RLM载体传递免疫保护性Mtb蛋白
比通过重组病毒载体传递或使用强有力的佐剂更有效。
本应用的目的是优化表达4Mtb的LM载体疫苗的表达
抗原;将其抗原库扩大到六种抗原,以增加其效力;并评估优化的
作为一种独立疫苗和作为一种
卡介苗免疫小鼠、豚鼠和非人灵长类动物的异种强化疫苗(NHP)
肺结核病模型。我们将通过以下方式实现这一目标:a)优化蛋白质表达盒
RLmMtb4Ag疫苗;系统评价新的Mtb抗原的免疫原性和免疫效果
小鼠,选择前两个抗原,随后构建rLmMtb6Ag铅疫苗候选;b)
对优化的rLmMtb6Ag候选疫苗进行全面的概念验证研究
在小鼠模型中作为单独和异种加强疫苗的安全性、免疫原性和有效性
肺结核病;c)作为一个标准,对主要的rLmMtb6Ag疫苗进行选定的概念验证研究-
孤立型和异种佐剂疫苗在豚鼠肺炎模型中的安全性、免疫原性和有效性
肺结核病;以及d)由于AERS需要在NHP中进行概念验证,疫苗才能进入临床前开发-
评估领先的rLmMtb6Ag候选疫苗作为独立疫苗的安全性、免疫原性和
与AERAS、BIOQUAL和杜兰国家灵长类动物合作的NHP肺结核病模型的疗效
研究中心。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCUS AARON HORWITZ其他文献
MARCUS AARON HORWITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCUS AARON HORWITZ', 18)}}的其他基金
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10115911 - 财政年份:2021
- 资助金额:
$ 120.07万 - 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10372028 - 财政年份:2021
- 资助金额:
$ 120.07万 - 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10570976 - 财政年份:2021
- 资助金额:
$ 120.07万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10462669 - 财政年份:2020
- 资助金额:
$ 120.07万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10120412 - 财政年份:2020
- 资助金额:
$ 120.07万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10685383 - 财政年份:2020
- 资助金额:
$ 120.07万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10267736 - 财政年份:2020
- 资助金额:
$ 120.07万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
10837445 - 财政年份:2019
- 资助金额:
$ 120.07万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
10308602 - 财政年份:2019
- 资助金额:
$ 120.07万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
9815937 - 财政年份:2019
- 资助金额:
$ 120.07万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 120.07万 - 项目类别: